Cargando…

Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment

PURPOSE: To explore the factors that influence the short-term clinical outcome after the first (131)I treatment of papillary thyroid micro carcinoma (PTMC). PATIENTS AND METHODS: From October 2015 to June 2018, patients who were diagnosed with PTMC with lymph node metastasis were analyzed retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jingjia, Yun, Canhua, Zhu, Xiaolu, Li, Xiao, Sun, Yaru, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214364/
https://www.ncbi.nlm.nih.gov/pubmed/34163244
http://dx.doi.org/10.2147/CMAR.S308012
_version_ 1783710048854212608
author Cao, Jingjia
Yun, Canhua
Zhu, Xiaolu
Li, Xiao
Sun, Yaru
Zhang, Wei
author_facet Cao, Jingjia
Yun, Canhua
Zhu, Xiaolu
Li, Xiao
Sun, Yaru
Zhang, Wei
author_sort Cao, Jingjia
collection PubMed
description PURPOSE: To explore the factors that influence the short-term clinical outcome after the first (131)I treatment of papillary thyroid micro carcinoma (PTMC). PATIENTS AND METHODS: From October 2015 to June 2018, patients who were diagnosed with PTMC with lymph node metastasis were analyzed retrospectively, excluding patients with incomplete clinical data, distant metastasis, positive TGAb, TSH<30 mIU/L. The baseline data of sex, age, time from last surgery to first (131)I treatment, tumor pathology information, and biochemical information were collected before admission. All patients included had radioactive iodine (RAI) with 3.70 GBq. The treatment response of patients was evaluated 6–8 months after discharge. By means of univariate and multivariate analysis, including excellent response (ER) and non-excellent response (NER) groups of clinical data, we assessed the impact of (131)I on patients’ outcome. A nomogram model was established based on the above independent risk factors. RESULTS: A total of 206 patients (59 males and 147 females, mean age 43.4 ± 10.6 years) were included in the study. The median follow-up time was 169.4 ± 10.5 days, including 139 patients in ER group (67.4%) and 67 patients in NER group (32.5%). Four factors including combining Hashimoto’s thyroiditis, pre-ablative Tg levels, UIE levels, and lateral lymph node numbers were statistically different between ER group and NER group with significance at P < 0.05. Further multivariate analysis showed that Hashimoto’s thyroiditis and Ps-Tg levels could be used as independent factors. The model verification showed that the C-index of the modeling set was 0.822, indicating that the nomogram model had a good predicted accuracy. CONCLUSION: Our data suggest that coexisting Hashimoto’s thyroiditis and elevated Ps-Tg levels are predictive factors for short-term outcome of thyroid micro papillary carcinoma after (131)I treatment. Also, the nomogram model had a good predicted accuracy.
format Online
Article
Text
id pubmed-8214364
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82143642021-06-22 Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment Cao, Jingjia Yun, Canhua Zhu, Xiaolu Li, Xiao Sun, Yaru Zhang, Wei Cancer Manag Res Original Research PURPOSE: To explore the factors that influence the short-term clinical outcome after the first (131)I treatment of papillary thyroid micro carcinoma (PTMC). PATIENTS AND METHODS: From October 2015 to June 2018, patients who were diagnosed with PTMC with lymph node metastasis were analyzed retrospectively, excluding patients with incomplete clinical data, distant metastasis, positive TGAb, TSH<30 mIU/L. The baseline data of sex, age, time from last surgery to first (131)I treatment, tumor pathology information, and biochemical information were collected before admission. All patients included had radioactive iodine (RAI) with 3.70 GBq. The treatment response of patients was evaluated 6–8 months after discharge. By means of univariate and multivariate analysis, including excellent response (ER) and non-excellent response (NER) groups of clinical data, we assessed the impact of (131)I on patients’ outcome. A nomogram model was established based on the above independent risk factors. RESULTS: A total of 206 patients (59 males and 147 females, mean age 43.4 ± 10.6 years) were included in the study. The median follow-up time was 169.4 ± 10.5 days, including 139 patients in ER group (67.4%) and 67 patients in NER group (32.5%). Four factors including combining Hashimoto’s thyroiditis, pre-ablative Tg levels, UIE levels, and lateral lymph node numbers were statistically different between ER group and NER group with significance at P < 0.05. Further multivariate analysis showed that Hashimoto’s thyroiditis and Ps-Tg levels could be used as independent factors. The model verification showed that the C-index of the modeling set was 0.822, indicating that the nomogram model had a good predicted accuracy. CONCLUSION: Our data suggest that coexisting Hashimoto’s thyroiditis and elevated Ps-Tg levels are predictive factors for short-term outcome of thyroid micro papillary carcinoma after (131)I treatment. Also, the nomogram model had a good predicted accuracy. Dove 2021-06-14 /pmc/articles/PMC8214364/ /pubmed/34163244 http://dx.doi.org/10.2147/CMAR.S308012 Text en © 2021 Cao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Cao, Jingjia
Yun, Canhua
Zhu, Xiaolu
Li, Xiao
Sun, Yaru
Zhang, Wei
Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
title Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
title_full Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
title_fullStr Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
title_full_unstemmed Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
title_short Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After (131)I Treatment
title_sort clinical analysis of the short-term outcome of papillary thyroid micro carcinoma after (131)i treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214364/
https://www.ncbi.nlm.nih.gov/pubmed/34163244
http://dx.doi.org/10.2147/CMAR.S308012
work_keys_str_mv AT caojingjia clinicalanalysisoftheshorttermoutcomeofpapillarythyroidmicrocarcinomaafter131itreatment
AT yuncanhua clinicalanalysisoftheshorttermoutcomeofpapillarythyroidmicrocarcinomaafter131itreatment
AT zhuxiaolu clinicalanalysisoftheshorttermoutcomeofpapillarythyroidmicrocarcinomaafter131itreatment
AT lixiao clinicalanalysisoftheshorttermoutcomeofpapillarythyroidmicrocarcinomaafter131itreatment
AT sunyaru clinicalanalysisoftheshorttermoutcomeofpapillarythyroidmicrocarcinomaafter131itreatment
AT zhangwei clinicalanalysisoftheshorttermoutcomeofpapillarythyroidmicrocarcinomaafter131itreatment